for "nightly business report," i'm meg terrell. >>> glaxo sinks on concerns about its dividend. that's where we begin tonight's market focus. glaxo posted higher quarterly results helped by consumer health care products. the company said it would consider a bid for pfizer's over the counter business should pfizer put it up for sale. but the prospect of that kind of deal could top $10 billion. that stoked fears of a dividend cut. that sent glaxo shares down 6% to $38.19. >>> profit at the world's largest biotech company amgen beat wall street expectations, helped by lower costs and higher operating margins, helping offset a drop in sales of the company's more established products. amgen raised its full year adjusted profit forecast despite taking a hit to its puerto rico operations from hurricane maria. shares initially fell following the after the bell earnings and also ended the regular session down about 1.5% to $177.50. >>> shares of advanced microdevices continued to get hammered today following the company's earnings which came out late yesterday. the chip maker's profit an

for "nightly business report," i'm meg terrell. >>> frito-lay helps lift the bottom line at pepsi. and that's where we begin tonight's market focus. the food giant reported a better than expected profit thanks in part to selling more snacks. but weakness in its north american bevere business caused overall sales to disappoint. the cfo of the company says it focused too much of its marketing efforts on newer products, and it will fix that mistake. >> we really had a strong pipeline of innovation this year. and we probably just moved too many resources from our core businesses of pepsi and dew into these new products. and frankly that cost us competitively for the quarter. we'll need to balance that out a little bit better over the next couple of quarters. >> pepsi shares finished up 21 cents today to $109.34. >>> office depot is buying i.t. provider compucon, part of a plan for office depot to transition to a broader business c said it was cutting its guidan for 2017 due to hurricane disruptions. office depot shares were off almost 18% to $3.78. >>> shares of gopro got crushed today

meg terrell joins us onset to talk about it. where do we start with this story? >> let's start with this report from "the wall street journal." this would be a gigantic deal, $200 a share. we'll note aetna's stock didn't trade up that high. it implies the market might not relieve this yet. that would be a 25% premium to where the stock was trading. thinking about what this means for cvs, they already are both a pharmacy benefits manager, so managing drug benefits for employers and insurers, and they're a retail pharmacy, of course. this would make them yet another thing, giving them more power to potentially offer to employers when trying to do services with them. we've seen this with unitedhealth, which also has a pbm in-house. these companies are getting bigger and bigger, trying to get more ability to offer things to their customers. >> there has been sort of a lot of sort of subcontracting. are we about to see a consolidation, or maybe even a situation where not only do insurers merge with the pharmacy benefit managers merge with medical systems, health care

meg terrell joins us >> hi, guys. the biotech window is pretty wide open right now in terms of third quarter results just reported by renaissance capital on health care ipos, they accounted for almost half of ipos in the quarter, helping drive outsize returns there. for health care there were 14 ipos in that quarter with an average return of 57%. in terms of the pace of biotech ipos, people i'm speaking with say they are picking up but it's not getting to an overexuberant level like we saw back in 2015, 2014 of course that was the top of the biotech market, the middle of 2015. we have a chart showing the number of ipos tracked against the ibb performance. you can see in the second quarter of 2015, that was a peak in the number of ipos. then the market peaked after that that was when the drug pricing rhetoric heated up in terms of policy topics and ipos slowed down a little bit after that now they're starting to pick back up again. we had three ipos in the last two weeks that have outperformed since they were priced nu

back to you. >> thank you, meg terrell at headquarters >>> our next guest says when it comes to amgen, stay calm and keep dying carter, hi >> hi there. this is the preeminent b biotechnology company. i think what's important is this as unhappy as this it, the next chart will put this drop in perspective. we see it's trading here at 173 post close now, take a look at the chart of amgen. this is a five-year chart, how it broke out this bottom trend line right here is exactly where the stock is indicated meaning it's probably already found the level that it's going to find. the key is that it flirted with breaking out once. often you get a little pullback, which we're getting. that's no big deal, i would say. and then the real bet is that ultimately the way forward is out of this formulation. so again, it doesn't done anything wrong as a biotech but a beat the market kind of stock and best in class in terms of biotech generally. let's talk about ibb and then i'm going to quilt. one-week performance, this column, one-month performance. biotech by far worse than health care, and health car

so the shares down about 6 3/4 percent there for celgene. >> sharp move, meg, thank you, meg terrell at headquarters. it's a buy, maybe. >> quick kudos to goldman sachs who yesterday said investors should rotate out of celgene >> because of the irritable bowel -- because of crohn's disease? >> i'm not certain if that was the case quickly, quickly, i'm not certain what they had factored into the crohn's disease in my opinion this is an overreaction in the aftermarket. >> night after night on this desk we see one of these blowups or you see the stock get dragged under, you look at the ibb that's still up 25% year to date, it lets you know you probably shouldn't be in a single stock, you should be in the ibb. because you get all these names without the individual risk of one name having an afterhours blowup like this >>> coming up next, talk about a bad apple. the stock getting crushed among reports of slowing iphone 8 sales. a top technician weighs in >>> twitch is the most watched network in the world, more than hbo, espn, even netflix. emmett shear is here >>> and the moment investor

thank you, meg terrell on gilead we saw the decline in shares of celge celgene, what a sharp decline,hat hurt the entire level >> gilead is back to pre-kite levels they're in the hot space 8 cv, we knew this business, as meg pointed out, that sounded light, sounded extremely light hiv is better. i think people are concerned about m&a still. i think people still expect more to happen in this space and they're not -- >> if it's going to happen last night carter worth liked where the charts were setting up right nowamgen, yes. >> even though they had some declines in sales, we talked about the $41 billion last night. i think they're going to have to use that cash. we look at gilead and the pop they got out of kite now starting to fade back down again. still, that was a great acquisition they needed on cancer treatment i think this amgen chart is starting to set up, as carter was telling us those numbers, mel, that's room for m&a. maybe that starts to turn biotech around >> a week ago, the 19th, celgene came out and said they would discontinue the drug phase iii, discontinue the trial. th

a news alert on gilead let's get to meg terrell >> reporter: the fda has just approved gilead's newly acquired cancer drug. the drug is for non-hodgkins lymphoma it's an almost $12 million acquisition of kite pharma earlier this year. this is the second in a new form of immunotherapy cancer drugs where you take a patient's own cells and modify them to better detect cancer, then giving them back, a one-time treatment gilead has announced the price, in the united states it's going to be $373,000 now, that probably soults a lot but novartis' drug approved earlier this year, they priced at $475,000, guys, so we're watching gilead, they're up about 1% in after hours on this news >> did you say it was a one-time treatment? >> reporter: that's right, they take the cells out, fix them up and give them back it is designed to be a one-time treatment. >> wow meg, thanks, meg terrell guy adami, they had one-time treatments for their hep franchise. and it was amazing for them. >> it was amazing until it wasn't amazing, it forced them to make this deal. now, if they had -- if kite's drug had failed

meg terrell joins us with more. this is the most amazing story. >> reporter: it's a really incredibly story, and a milestone in the field of medicine. gene therapy represents a whole new way to treat disease. ges desigd to be a one-time remedy. it uses a virus to deliver a healthy copy of a gene to make up for the one that causes the disease. sparks therapeutics could be the first to bring gene therapy to the market if the fda approves the drug. the panel voted 16-0 today that the drug has a favorable profile. it's designed to treat a congenital form of blindness. people with the condition eventually lose their sight. people who participated in the clinical trial told the fda panel today how much of a difference they felt after taking the treatment, with one person saying that before it was like she was looking through a tunnel, where is afterwards she could make out the stars for the first time. two siblings who participated in the trial last year. here is caroline carpenter sharing her experience. >> before, i cou

meg terrell has the second and final part of our modern >> reporter: mandy and james johnson say when it came to treating their daughter caitlin's cancer, no price would have been too high. >> money would have never been a deciding factor. >> reporter: after 2 1/2 years of chemotherapy failed her, caitlin found success with an experimental treatment that used her own immune cells to cure her leukemia. the fda approved it august 30th. the price, $475,000. even at a time of eye popping drug prices, that number raised eyebrows. doctors at memorial sloan kettering said it, quote, shattered oncology drug pricing norms. the medicine is unique in several ways. each patient's therapy is made from her own immune cells, requiring a more complex manufacturing process. the price is for a one-time treatment. and the number of patients for whom the drug is approved is small, about 600 people in the u.s. each year. >> a new type of medicine like this, and there will be so many out there that are administered just once and for profound benefit, really require us as a community to identify, you know,

for "nightly business report," i'm meg terrell. >>> amazon is reportedly getting serious about taking on youtube, and that is where we begin tonight's market focus. amazon is working toward creating more advertising friendly initiatives to compete against youtube. one program could potentially give advertisers more data on what viewers are watching and doing online. amazon is up today. and walmart wants to make online returns easier. the retail giant said customers will be able to use the walmart app to speed up the process, cutting down return time to 30 seconds. shares of walmart up about 2% on the session to $80.53. honeywell reportedly will spin off the noncore asset and create at lieb two new publicly traded reuters said the company will resist calls by one of the influentia investors to spin off the space unit. >>> the subprime lender one main is reportedly in talks to sell itself in a deal that could be worth about $4 billion. "the wall street journal said one main is said to be in advance talks with a number of interested parties, although there is no guarantee of the deal. on

meg terrell is here now.ing at pharmacy benefits because with cvs looking at aetna, a lot of it has to do with am azblon and -- i hope besos agood guy deep down. >> he is he is. >> i hope so because he is going to be, you know -- he is going to be one of the most powerful people on the planet he probably already is, right? >> he is a good guy. do we have to worry? >> i'm sure he is a great guy. he is definitely one of the most powerful on the planet as far as getting into some of these other areas, you know, we'll see on the pharmacy side there's a lot of regulation there. a lot of red tape. you know, he will give you an example there. they're in the business of shipping wine across state lines right now, and they're looking at getting out of that because they think that has too much regulation i'm not 100% convinced they're going to be getting into the pharmacy space, but we'll see. >> so, michael, amazon obviously steps in they bet into the supermarket space with the purchase of whole foods over the course

meg terrell is here looking at johnson & johnson. wolf, we begin with you. two beats but the stocks are moving in opposite directions. symbol exactly right, melissa. let's start with the fundamentals goldman sachs beat earnings on the top and bottom line. the recent poor performance in fix income currencies and commodities trading turned and rose quarter on quarter, albeit still down 26% year on year. however, the vast majority of the revenue sxechlt ps beat for goldman sachs came in the investing and lending business, described as "low quality area" by nimura's analyst steven chuback. goldman also revealed an increase is coming in the second quarter of 2018 as well as its previously undisclosed approval to buy back over 7 xwl in stock next year. some had hoped for a bigger potential number than that meantime, morgue stanley produced another quarter of strong results across all of its businesses supported by good cost control the standout was wealth management where profit before tax margin came in at 26.5% ahead of the 25% target. partly due to cost control

tribe involved in a patent deal is now suing the two major tech giants over a separate patent issue meg terrelln following the story and is here to explain it, meg. >> reporter: despite a lot of backlash, the tribe is not backing down on the strategy today it filed patent infringement suits against microsoft and amazon they transferred from small tech company src labs which claims they've been infringing the ip for years. they're seeking damages and royalties. the mohawks are involved because of sovereign immunity held by tribes the patent challenges to a relatively new system. ipr. it's become a battleground in the tech and pharma world and the supreme court is due to hear a case soon on whether the system is constitutional now the system was created just six years ago through the america invents acts proponents argue it's a way to more quickly dismantle bad patents. the critics say it's enables companies to legal limbo by filing suit after suit that's the context in which they are partners with the tribe. effort from generic companies while if it fought on the same patents. of course monday a

a market flash on spark therapeutics meg terrell is in the newsroom with more. sounds a decisive vote >> reporter: pretty decisive, 16-0 in favor of this experimental therapy from spark therapeutics, the stock had already run up quite a bit, it was expected to be a positive panel. a sparks drug treats a rare inherited form of blindness. there were a lot of patient testimonies here in front of the fda today, talking about how much this therapy has changed their life in terms of bringing back their sight it doesn't make their sight perfect but it is widely expected to get approved by the fda. that decision is expected by january. the next question will be the price, millenniuel, people are g as high as $1 million. it is a rare disease >> $1 million for a course of treatment but it will cure the blindness. >> reporter: it will cure it significantly and it's expected it would only have to be one time >> thank you, medical terrell. >> wow >> wow >> that's a question for an ethics class, doesn't sound like a product you would actually choose >> this gets to a whole ot

. >> meg terrell there by the way, was just yelling across the room here only the trading floor, thearket on close orders show a slight bias to the buy side here of $300 million. so we're watching that i mean, for a moment ago, it looked like the dow was going to turn negative here on us it was losing altitude quickly, now we're back up ten points we'll see how we do that there, the s&p and nasdaq positive right now. >> dollar is weaker too. it's been the high performer of late really has caught up, got an lot of attention about this rotation this time of the year that people seem to be making out of the thing names that have done so well as big cap technology name into some of the smaller cap, more valued parts of the market which is why we are talking. but whether or not that's holding up with the energy story right now with crude below 50 a barrel today. >> as we mention, you know the president is in las vegas right now, meeting with first responders and jane wells is still in las vegas covering this story for us she has the very latest as we wait for the president, jane >> report

. >>> let's go to meg terrell who has a news alert. >> we are looking at nses therapeutics a director of that company has been arrested and charged with racketeering associated with the company's practices around the opioid-related drug fentanyl the stock down now almost 10%. this loads on top of previous charges against former executives of this company, insys. this is the first criminal action around the opioid crisis here in the united states. kapo kapour, the majority owner, is expected in federal court today. so insys back 10%. >>> let's get back to twitter and get some commentary from the desk what do we think here? >> personally -- >> this is one heck of a gain. >> it is and i think josh brings up the best point it's 50 million shares short the average daily volume is somewhere around 60 million. 50 million shares short. now look at the analysts coverage of it i think there's 36 major analysts that cover the stock. only three of them have a buy on it i think this is the unwind how long and how far that unwind of skepticism and negativity surrounding the stock can go, i don't kn

. >> we got meg terrell here onset talking about something similar.y're talking about a spin off? >> from industrial to the whole business sector now. >> it is not the biggest part of pfizer business. pfizer brought in $3.35 million in reserve news. wall street responseto the announcement was generally favorable and many speculating that the company could use the proceeds to fuel the acquisition of its own peculatio speculations swirl around bristol-myers. now, analysts said there could be a number of interested parties to buy the healthcare unit, from p & g and bayer ag and johnson&johnson. a little bit of antitrust headaches there if you will. >> at one point there was a reason for it and they seem to believe there is energy. what changed and what no longer they think should be apart of it >> this is something we have seen across the industry in favor of more hi innovative. >> so companies are kind of splitting up of what they say unlocking values of these things and separating the parts that investors can invest in different growth paces out in the

we want to bring in meg terrell of a look on that. >> that's right.n one of these kinds of patent challenges the lung cancer drug eli lilly >> of course we are seeing up of 2.8% there a lot of patent shaping out in the world today. >> that's specifically concerning it is part of a colossal of new pcs canine inhibiter for that class of drugs it is a good question. people are disappointed commercially and how these canine drugs have been doing so far and whether there is been any concerns among doctors to prescribe regeneron. this term in terms of the decision itself, the drug did not strike down the key arguments of the case this one is not over yet >> cigna is refusing to cover oxycontin. >> that's right, they announced this value based contract of an abuse detergent of oxycontin they're going to get a discount on the medication if the dose s dosage cig buo cigna is saying in a statement, drug companies don't control prescriptions, of course, guys, this comes through a ton of scrutiny in terms of their role and opioid crisis. last month, the state gen

louis that they have wholesale licenses in the works in 12 states jeffries today, note out of meg terrellin our view the entire supply chain is a structural short until amazon has proven to be an aneemic player do you tie this directly >> no, i already use amazon for some health supplements, they are so easy to use i just want -- i long for the day when your doctor goes on your amazon prime, types in the prescription and it comes the next day and i don't have to go pick it up at walgreen's, let me order this lir ka. i take the lyrica, it's good for you. when amazon does same day, i mean, can you imagine? what does rite-aid do. >> rite-aid has their share of issues, they are selling stores to walgreens that got turned down by the antitrust and made clear that we can't get larger in pharmacy and retail, we have to look to other areas i should mention cnbc.com confirmed as well the talks. when we know they are going on, i don't have a lot to add. >> by the way, jim, wouldn't have to leave the drugs outside. >> that's right. >> i'll give them the key. so happy -- i trust them more than i trus

ceo mark parker in an exclusive interview on closing bell and it's another busy hour for earnings meg terrell covering for us. kate rogers will bring us the latest from buffalo wild wings and contessa brewers will have the numbers from las vegas fans. first let's talk about this sell off today. joining us, markets commentator as always, mike santulli, danny hughes, and paul hicky from the spoke investment group dow closing off the lows, we were down 191 points at the lows of the day we've got leaders like nike, the company laying out plans for new growth targets it helped the dow turn around a bit late in the trading day. the latter there, boeing, the company did take a $329 million tinker program charge, and it has been a big winner overall this year. for the s&p, it is fleur systems at the top and chipotle falling behind after disappointing earnings, mike, another earnings story. >> yeah, it was. i think you saw what i think is typical sell on the news responses to stocks that have been up a lot going into earnings, since i think that weighed on some of the indexes today, but also just a ma

joining us now for for on the water, johnson & johnson cfo, and meg terrell is on the set with us.ou did raise your full year guidance to $7.25 to $7.30 what was the previous guidance range? >> it was about 10 cents lower than that, joe >> you beat by ten cents in the quarter. so you're not really increasing fourth quarter results >> joe, we had a great quarter we had some new acquisitions and -- they did extremely well, and we will invest in the back half of the year and get them set up for a strong future growth potential as well >> you made up the 10 cents that you increased just in the third quarter. is that correct? >> we increased our outlook on both sales and earnings for the full year above the analyst estimates, although we beat the analyst estimates in had the third quarter, we were pretty much in line with what we thought we would do and were confident that we're going it continue to grow into fourth quarter and beyond as well >> sales grew at 3.8%. >> each one was exactly -- that shows you that this is kind of an intalastic, i guess, company to some extent and what you